Real-World Use of Oritavancin for the Treatment of Osteomyelitis

Patrick J. Scoble1 · Joseph Reilly2 · Glenn S. Tillotson3

Published online: 25 June 2020 © The Author(s) 2020

Abstract

Osteomyelitis is a difficult-to-treat disease that can require both surgical debridement and a prolonged course of antimicrobial therapy. Current standard of care for the antimicrobial treatment of osteomyelitis is fraught with multiple challenges and limitations. Patients typically require the insertion of an indwelling catheter for single or multiple daily intravenous antibiotic infusions for up to 6 weeks. Currently, there are treatment guidelines for only vertebral osteomyelitis, indicating the complexity of the condition. Oritavancin is a long-acting, second-generation lipoglycopeptide, administered intravenously once per week, which has potential to be a useful alternative in the treatment of osteomyelitis. This article reviews occurrence and outcomes of off-label oritavancin use for treatment of osteomyelitis as described in case reports. Analysis included 23 patients treated for osteomyelitis with single- or multiple-dose oritavancin. Overall, clinical cure or improvement was achieved in 87% of patients, and adverse events were mild and reported in only two patients. Clinical efficacy was demonstrated in 81.8% of methicillin-resistant Staphylococcus aureus (MRSA), 71.4% of methicillin-sensitive S. aureus (MSSA), 50% of vancomycin-resistant Enterococcus (VRE), and in the single case of Streptococcus pyogenes. Oritavancin has shown efficacy against Gram-positive pathogens in osteomyelitis, and offers a possible outpatient treatment option for osteomyelitis patients. Future studies are needed to determine dosing frequency in osteomyelitis patients.

Key Points

- Review of case studies of off-label use of oritavancin for osteomyelitis has shown clinical success against Gram-positive pathogens in osteomyelitis, and it should be considered an effective treatment option.
- Oritavancin could offer a more patient-friendly treatment option as it can be administered intravenously (IV) once a week compared to daily IV treatment for multiple consecutive days or oral tablets, thus reducing impact on daily activities, and potentially reducing the length of hospitalization or avoiding it.
- Future studies are needed to explore outpatient use of oritavancin for osteomyelitis treatment, the possible pharmacoeconomic benefits and patient impact.

1 Introduction

Osteomyelitis is an infectious, inflammatory disease of the bone that remains difficult to treat, typically requiring a prolonged course of intravenous (IV) antibiotics [1]. The incidence of osteomyelitis has been reported to be as high as 21.8 cases per 100,000 person-years, and was higher for men than for women and increased with age (p < 0.001) [2]. Over a 40-year period, annual osteomyelitis incidence rates have increased from 11.4 cases to 24.4 per 100,000 person-years (p < 0.001) [2]. Osteomyelitis occurs when microorganisms invade previously healthy bone, leading to an inflammatory response and concomitant destruction of the bone, which are the hallmarks of osteomyelitis [3–5]. Antibiotics poorly penetrate dead bone and infected fluids; surgical treatment with debridement of the necrotic bone accompanied by the identification of the infectious etiology, via surgical sampling or needle aspiration, allows for the optimization of antibiotic therapy [5, 6]. There are two major classification schemes for osteomyelitis [6, 7]: The Lew and Waldvogel [6] system classifies osteomyelitis by duration of disease—either acute or chronic, as well as infection mechanism—hematogenous or contiguous infection. Histopathology of osteomyelitis rather than duration of illness is used to categorize whether osteomyelitis is chronic or acute [8]. Acute osteomyelitis is defined as...
infection occurring before the development of sequestra, which usually occurs within 2 weeks of initial disease onset [9]. Chronic osteomyelitis is defined as longstanding infection that evolves over months or even years, characterized by the persistence of microorganisms, low-grade inflammation, and the presence of dead bone and fistulous tracts [4, 6]. Clinical signs persisting for longer than 10 days are associated with the development of necrotic bone and chronic osteomyelitis. Chronic osteomyelitis may also present as a recurrent or intermittent disease, with periods of dormancy of variable duration [10, 11]. Additionally, osteomyelitis classification is divided into one of two categories (defined by physiologic mechanism): contiguous dissemination (trauma, surgery, or prosthetic hardware), or via hematogenous seeding. Contiguous osteomyelitis is further subdivided into whether or not there is vascular insufficiency [3, 6]. The gold standard for diagnosing osteomyelitis is bone biopsy and tissue culture; however, these invasive procedures often prove prohibitive—indeed chronic osteomyelitis remains challenging to diagnose, and clinicians use a combination of clinical symptoms, laboratory, radiographic, and microbiological findings to do so.

The Cierny-Mader scheme classifies osteomyelitis by anatomic stages and patient health status, in order to provide patient management guidance. Stages 1–4 describe anatomic location and progression, and host health status categories by local and systemic factors that affect immune surveillance, metabolism, and bone vascularity [7, 10].

While other causative pathogens have been identified in osteomyelitis, *Staphylococcus aureus*, in particular methicillin-resistant *S. aureus* (MRSA), is among the most common. MRSA has advantageous features for bone infection; an array of virulence factors (including the production and release of cytotoxins), enhanced pathogenesis, and biofilm formation, while concomitantly impairing host/immune response [7]. Co-morbidities impairing peripheral blood flow, including diabetes mellitus, may make osteomyelitis in these patients even more difficult to treat [5, 6].

Osteomyelitis treatment usually includes the use of prolonged, high-dose, IV antibiotics [1, 12–16]. However, this tactic must be balanced against antimicrobial stewardship to avoid resistance, as well as the risks associated with IV catheters, and costs accompanying agents themselves [12, 17]. There is a paucity of randomized, clinical trials to suggest the use of a single antibiotic or combination of agents for osteomyelitis in adults, and the optimal route and duration of antibiotics with osteomyelitis remains ill-defined due to limited prospective clinical trials. Most experts in the USA recommend 4–6 weeks of IV antibiotic therapy for osteomyelitis [1, 12–15]. Once the patient is stable for discharge, treatment can be continued, either administered via outpatient parenteral antibiotic therapy (OPAT) with substantial vascular access, such as a peripherally inserted central catheter (PICC), or transition to a suitable oral alternative [18].

Vancomycin is usually the core of IV therapy, particularly for MRSA infections. However, vancomycin use is challenging because of the weight-based dosing, dosing frequency, the necessity of single and multiple daily doses, the need for therapeutic drug-level monitoring and for vascular access, and toxicities associated with its use [16, 19, 20]. Other antibiotic therapies available have adverse events that can develop with prolonged use, or limit their usage in certain populations. Development of neutropenia and thrombocytopenia is associated with extended use (> 14 days) of ceftaroline or linezolid, respectively [21, 22], and linezolid treatment for > 28 days can cause lactic acidosis and optic neuritis [23]. Additionally, linezolid patients concurrently taking selected serotonin reuptake inhibitors can develop serotonin toxicity, and concurrent monoamine oxidase inhibitor use has been associated with hypoglycemia [24–26]. Daptomycin can cause elevated creatinine phosphokinase (CPK), myopathies, or eosinophilic pneumonia [22]. Delafloxacin is an effective agent that requires a loading dose—it also has a better safety profile than other fluoroquinolones; however, the fluoroquinolone warning issued by the US Food and Drug Administration (FDA) is still applicable [27].

In addition, many antibiotics, including vancomycin, often have difficulty penetrating biofilm formations and most fail to penetrate bone. When long-term treatment courses are necessary, availability of antibiotics with longer dosing intervals, fewer toxicities, and minimal to no requirement for monitoring therapeutic drug levels, would be preferred.

Oritavancin is a long-acting, semi-synthetic, second-generation lipoglycopeptide approved by the FDA for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) [28–30]. The pharmacokinetic/pharmacodynamic (PK/PD) data showed that administration of a large, single 1200 mg dose of oritavancin was safe, well tolerated, and optimizes concentration-dependent killing against several Gram-positive organisms, resulting in more effective and pronounced bactericidality as compared with the smaller, originally traditional doses and dosing schemes of vancomycin [31, 32]. The large volume of distribution of oritavancin and penetration into bone are favorable for exploring its use in osteomyelitis. Oritavancin demonstrates potent in vitro activity against most Gram-positive organisms, most notably *Staphylococcus*, *Streptococcus*, and *Enterococcus* species [32, 34–36]. The in vitro bactericidal activity of oritavancin against stationary-phase *S. aureus* cells, and sterilization of biofilms, is a particularly appealing feature when treating osteomyelitis with or without the addition of prosthetic devices and hardware [37]. Specifically, against enterococci, oritavancin is only approved for vancomycin-susceptible *Enterococcus faecalis* [30]. However, oritavancin also has activity against other *Enterococcus*...
species, including vanA-producing vancomycin-resistant Enterococcus faecium (VRE) [36, 38].

Oritavancin has favorable PK/PD, achieves wide distribution and penetration, and has potent in vitro activity against common osteomyelitis-causing pathogens. Additionally, a PICC is not necessary. These features make oritavancin a potentially useful option for the treatment osteomyelitis, although the physiological complexity, severity, and recurrence of these infections will likely require more than a single dose. The use of oritavancin in the off-label treatment of osteomyelitis is currently restricted to a series of case reports, which show that multiple doses of oritavancin are safe and effective in the treatment of osteomyelitis caused by VRE, MSSA, and MRSA [39–46]. We present the reported outcomes of multiple-dose oritavancin therapy in patients with osteomyelitis.

2 Methods

This was a comprehensive literature review of microbiologically positive patients who received oritavancin for the treatment of acute or chronic osteomyelitis. Searches of PubMed and Google Scholar for papers, case reports, or other available data were conducted using the following search terms: “osteomyelitis” and “oritavancin”; “osteomyelitis” AND “oritavancin” AND “off-label”; osteomyelitis AND oritavancin AND off-label AND multiple dose. This search identified 17 resources in PubMed and in Google Scholar 73 additional (not duplicate) resources. These were reviewed and reduced to only resources that included cases of osteomyelitis and treatment with single or multiple doses of oritavancin. Reports were included if patients had a microbiologically confirmed osteomyelitis infection and were treated with oritavancin. A total of 38 cases were retrieved for analysis; 20 from seven published papers and 18 from the Clinical and Historic Registry and Orbactiv Medical Evaluation (CHROME) registry. From the 38 cases, 23 had microbiologically confirmed osteomyelitis infections and were included in the final review.

Both “clinical cure” and “clinical success” were used interchangeably throughout the analyzed literature and had the same definition: resolution of clinical signs and symptoms of infections, wound closure, resolution of fever, normalization of white blood cell count, no additional infection-related hospital admission, surgical debridement or amputation, no need for additional antibiotic therapy for the indication for which oritavancin was initially administered. Clinical “cure” or “success” are identified within the tables; however, we consider them under the same definition as clinical cure. Clinical improvement was defined as recovery from infection with need for additional Gram-positive therapy after completion of oritavancin treatment. Clinical failure was defined as inadequate resolution or progressive worsening of infection, and need for continued or alternative Gram-positive therapy at completion of oritavancin therapy, or loss at follow-up.

3 Results

Seven papers and cases from the CHROME registry were used for our analysis, which included 23 patients with microbiologically confirmed infections who received oritavancin for the treatment of osteomyelitis. These chart reviews and case studies reported administration of oritavancin, but not why it was selected by the clinician. However, clinical status of the patient, anatomic location of the infection, patient availability for follow-up, safety of other available treatments, and relevant co-morbidities would have been considered. Patients who received only one or two doses of oritavancin were still included because they were deemed to either exhibit clinical improvement or were a clinical success (Tables 1, 2, 3, 4, 5). The median age was 50 years (range 26–98 years), and 54% (13/23) were female. The most common co-morbidities were diabetes mellitus and hypertension. Osteomyelitis was confirmed in patients by either nuclear bone scans or by MRI. A total of 14 patients (56%) had documentation of antimicrobial treatment prior to administration of oritavancin, and one patient received concurrent doxycycline. All patients received at least one 1200 mg dose of oritavancin, and the majority (22) of patients received one 1200 mg dose followed by at least two further 1200 mg doses over a varied timeline (Tables 1, 2, 3, 4, 5).

The most common pathogen was MRSA, which was isolated in 48% (n = 11) of patients. Overall, clinical cure was achieved in 65% of patients (n = 15/23); however, clinical improvement was also demonstrated among patients—when combined, the overall rates of clinical success increased to 87% (n = 20/23).

Three clinical failures were documented. One osteomyelitis patient with confirmed MRSA, E. faecalis, and E. coli, who had received trimethoprim/sulfamethoxazole (TMP/SMX) therapy prior to one 1200 mg dose of oritavancin, was considered a treatment failure, and was then switched to ciprofloxacin and doxycycline. The second patient had a confirmed osteomyelitis MRSA infection, and oritavancin was given at two doses of 1200 mg every 9 days, which was switched to doxycycline after failure. The third patient was an active intravenous drug user (IVDU), and over a period of 71 days experienced multiple treatment failures. Initially administered vancomycin and cefazolin, once osteomyelitis infection was confirmed as MSSA this was reduced to just cefazolin; on day 8 of treatment, one 1200 mg dose of oritavancin was given.
Table 1  Patients receiving oritavancin to treat culture-positive osteomyelitis—results per pathogen, methicillin-resistant *Staphylococcus aureus*

| Reference                     | Sex/age (years) | Site of infection | Antimicrobials prior to oritavancin | Oritavancin dosing regimen | Concomitant antimicrobials | Outcome              | Time of follow-up | Adverse events |
|-------------------------------|-----------------|-------------------|-------------------------------------|----------------------------|----------------------------|------------------------|-------------------|-----------------|
| Chastain et al. [44]         | M/65            | Right great toe   | None                                | 1200 mg x 2; on days 1 and 13 | Doxycycline x 3 months    | Clinical cure          | 6 months | None reported |
|                               | M/31            | Left distal meta-tarsal | Clindamycin x 1 week               | 1200 mg x 3 on days 1, 52, and 90 | None                      | Clinical cure          | 6 months | None reported |
|                               | M/47            | Right distal first metatarsal | Clindamycin x 1 week, then doxycycline x 3 months | 1200 mg x 2; on days 1 and 72 | None                      | Clinical cure          | 6 months | None reported |
|                               | F/89            | Left lateral malleolus | None                                | 1200 mg x 4; on days 1, 36, 73, and 147 | None                      | Clinical cure          | 6 months | None reported |
|                               | M/62            | Right calcaneus   | None                                | 1200 mg x 6; on days 1, 14, 28, 70, 84, and 113 | None                      | Clinical cure          | 6 months | None reported |
| Ruggero et al. [41]          | M/46            | Native, vertebral osteomyelitis | Aztreonam, vancomycin, metronida-zole, doxycycline, TMP/SMX | 1200 mg every 2 weeks x 4 doses, then 1200 mg 1 month later | TMP/SMX | Clinical improvement | 5 months, and 1 year | None reported |
| CHROME Registry [46]         | F/47            | Not specified     | TMP/SMX                             | 1200 mg x 1                   | None                      | Failure                | N/A               | None reported |
|                               | F/70            | Not specified     | None                                | 1200 mg x 10 doses every 7–8 days | None                      | Clinical improvement | N/A               | None reported |
|                               | F/46            | Skull             | Vancomycin                          | 1200 mg x 6 doses every 7–14 days | None                      | Clinical cure          | N/A               | None reported |
|                               | M/58            | Left foot         | Minocycline, vancomycin             | 1200 mg x 1, then in 14 days, AE occurred with second dose | Linezolid                 | Clinical improvement | N/A               | Infusion discontinued; moderate, not serious infusion-related reaction; sent to ED for observation |
|                               | F/47            | Not specified     | None                                | 1200 mg x 2 doses every 9 days | TMP/SMX                   | Failure                | N/A               | None reported |

*M* male, *F* female, *TMP/SMX* trimethoprim/sulfamethoxazole, *AE* adverse event, *ED* emergency department, *N/A* information not available
and the patient was discharged on oral clindamycin. This patient then returned on day 50 of treatment, reporting non-adherence to clindamycin, and cephalexin was given for 1 month. At day 71 the patient presented with recurrent and worsening infection and eventually was discharged on TMP/SMX and rifampin for 3 months. Two months later the patient returned and a small aortic valve vegetation was identified alongside osteomyelitis; cefazolin was

△ Adis
initiated followed by chronic suppressive therapy with cephalaxin. All treatment failure cases received a regimen of only one or two doses of oritavancin, which is inconsistent with osteomyelitis treatment guidelines, which suggest 4–6 weeks of antimicrobial treatment [47].

All patients were included in the safety analysis. Oritavancin was well tolerated with adverse events (AEs) reported in only two cases (8.7%). One patient developed a moderate, infusion-related reaction during the second dose of oritavancin; the infusion was stopped and the patient was sent to the emergency department (ED) for observation and switched to linezolid. The second patient, who received only two oritavancin doses, was found to have anemia and leukopenia, and was transitioned to doxycycline for an additional 10 days. Clinical improvement was demonstrated in both patients prior to terminating oritavancin therapy due to AEs.

4 Discussion

Osteomyelitis remains a difficult to treat infection with significant treatment challenges, commonly requiring both surgical debridement and concomitant antibiotic therapy with agents active against the bone-infecting pathogen. MRSA is responsible for the majority of cases of osteomyelitis, which can persist and/or recur in up to 40% of patients [48]. While vancomycin remains the most frequently selected antibiotic for the treatment of osteomyelitis [16], vancomycin use is associated with increased rates of failure and recurrence, likely due to its poor penetration into bone and biofilm formations, as well as the occurrence of vancomycin-intermediate S. aureus (VISA), heterogeneous VISA (hVISA), and S. aureus isolates with increasing minimum inhibitory concentrations (MICs) [49, 50]. Antimicrobial selection needs to consider whether the agent achieves adequate bone penetration, with bioavailable bone concentrations exceeding the pathogen MIC. Anatomical location of infected bone, as well as vascularity, which may be compromised, affects achievable bone concentrations. Oritavancin has been shown to rapidly penetrate osseous tissues in rabbit tibia models and drug levels are maintained for greater than 168 h. The active ratio of oritavancin in bone is still unknown; in this animal model, bone penetration, defined as the tissue to serum AUC_{0-168} ratio into bone matrix and bone marrow, was 1.7 and 3.1, respectively, which is higher than that of linezolid, vancomycin, teicoplanin, and dalbavancin [33]. One caveat to note is that the concentrations of oritavancin obtained in the rabbit study by Lehoux (and those of the cited comparators) represent total drug concentrations, and the active fraction of each drug in bone remains to be described [33]. Therefore, the PK/PD relationship of oritavancin in bone and other tissues should be interpreted with caution. These data provided the stimulus for using single and multiple oritavancin dosing in patients with osteomyelitis. Clinical outcomes of oritavancin treatment for osteomyelitis caused by MRSA, MSSA, VRE, and S. pyogenes from the analyzed case reports and data are collated in Tables 1, 2, 3, 4. Oritavancin has been shown to be efficacious in a wide range of Gram-positive bone infections, with a 1200 mg dose (occasionally, a continued 800 mg dose) administered once a week for 4–8 weeks, with few adverse events. In this review, we chronicled the efficacy, safety, and clinical outcomes of 23 pathogen culture-positive patients with osteomyelitis who were treated with oritavancin in published case reports and also from the CHROME registry. Bone biopsy and tissue culture are the gold standard of osteomyelitis diagnosis; however, the use of these methods can be challenging due to their invasive nature. Thus, in the reviewed case reports, real-world diagnostic methods were made using bone scans or MRI. Real-world evidence regarding oritavancin shows high rates of clinical success with both single or multiple doses to treat osteomyelitis, and is well tolerated with minimal adverse events, without need for therapeutic drug monitoring (Table 5). In ABSSSIs, recent studies have demonstrated the potential opportunity for oritavancin to facilitate early discharge for patients, as the IV infusions are once per week, and it has also been administered in the ED to avoid hospitalization of patients for IV treatment [51]. While certainly promising, these findings are limited by the number of case reports and the unique circumstances of each case, as well as the potential influence of prior or concomitant antimicrobial therapy to successful outcomes; thus, future analysis is needed. Additionally, these data may be useful in identifying the optimal dosing frequency, which remains to be established, and we suggest each regimen should be adapted for the management of individual patients.
Table 5  Summary of the real-world experience using oritavancin for microbiologically positive osteomyelitis

| Study                  | Patient background                                                                 | Pathogens                        | Oritavancin dose and duration                                                                 | Outcome          | Adverse effects                                      |
|------------------------|-------------------------------------------------------------------------------------|----------------------------------|------------------------------------------------------------------------------------------------|------------------|-----------------------------------------------------|
| Schulz et al. [32]     | 4 patients; median age 59 years (31–76); 25% male                                    | MSSA                             | 3 patients: 1200 mg × 1 dose, then 800 mg weekly ≥ 2 doses 1 patient: 1200 mg × 2/week          | Success×2        | Anemia and leukopenia in 1 patient                  |
| Chastain et al. [36]   | 12 patients, median age 65 years (47–79), 67% male, 67% DM                           | MRSA                             | 3 patients = 1200 mg × 1 dose 9 patients = 1200 mg × ≥ 2 doses                               | 100% Success     | None                                                |
| Foster et al. [37]     | 57 y/o M with osteomyelitis secondary to prosthetic hip replacement                  | Daptomycin non-susceptible VRE   | 1200 mg once weekly × 6 weeks                                                              | Success          | None                                                |
| Delaportas et al. [31] | 49 y/o F with right tibial osteomyelitis secondary to retained intramedullary nail | MSSA                             | 1200 mg once weekly × 6 weeks                                                                | Success          | None                                                |
| Ruggero et al. [33]    | 46 y/o M with native vertebral osteomyelitis                                         | MRSA                             | 1200 mg every 2 weeks × 4 doses, then 1200 mg 1 month later                                | Improvement      | None                                                |
| Dahesh et al. [35]     | 59 y/o M with hardware-associated vertebral osteomyelitis                            | Vancomycin-resistant and daptomycin NS E. faecium | 1200 mg weekly × 2 doses, then 800 mg weekly × 8 doses                                      | Improvement      | None                                                |
| Stewart et al. [34]    | 26 y/o F with sacral joint osteomyelitis; IVDU                                      | MSSA                             | 1200 mg × 1 dose                                                                             | Failure          | None                                                |
| CHROME Registry [38]   | 18 patients; mean age 58.4 years, 38.9% male, 77.8% prior antibiotics, 50% failure prior antibiotics | MRSA, MSSA, coagulase-negative Staphylococcus, E. faecalis, E. faecium, S. pyogenes | 10 patients = 1200 mg × 1 dose 8 patients = 1200 mg × ≥ 2 doses                             | Clinical success: Single dose: 90% Multi-dose: 87.5% | Moderate, not serious infusion-related reaction (in multidose patient) |

M male, F female, y years, MSSA methicillin-sensitive Staphylococcus aureus, MRSA methicillin-resistant Staphylococcus aureus, VRE vancomycin-resistant Enterococcus, NS non-susceptible, DM diabetes mellitus, IVDU intravenous drug user
5 Conclusion

We reported on 23 microbiologically positive patients who received oritavancin, either in single or multiple doses, for the treatment of osteomyelitis. Few adverse events were noted, and they were generally mild and reversible. Oritavancin treatment for osteomyelitis was generally safe, effective, and well tolerated, and was able to facilitate outpatient therapy. The clinical success in these patients suggests that use of oritavancin, given at 1200 mg or 800 mg in multiple doses, can be beneficial for the treatment of osteomyelitis. The long half-life of oritavancin lends itself to a convenient treatment for patients, as a once-per-week IV infusion, and may reduce the need for central line placement, which could have a positive impact on a patient’s quality of life. Future studies to evaluate the potential pharmacoeconomic benefits of oritavancin for osteomyelitis treatment, as well as the impact of infrequent IV infusions in the OPAT setting on patients’ lives and productivity, should be explored. Clinicians should consider the use of oritavancin in the treatment of those patients with osteomyelitis as a safe and efficacious option.

Acknowledgements The authors wish to thank Nicolette Theriault for her editorial assistance on this manuscript.

Author Contributions All authors had a role in study design, and in conceiving and writing the manuscript. According to the guidelines of the International Committee of Medical Journal Editors (ICMJE, www.icmje.org) all authors met the criteria for authorship and no deserving authors have been omitted.

Compliance with Ethical Standards

Funding No funding was received for the preparation of this manuscript. This article is part of a supplement wholly funded by Melinta Therapeutics.

Conflict of Interest P.J.S. serves as a consultant for Iterum Pharmaceuticals LTD, Shionogi & Co., LTD, and Spero Therapeutics. JR receives speaker fees from Melinta Therapeutics. GST serves as consultant to Melinta Therapeutics, Shionogi Inc, Summit plc, KBP Biosciences and Aim Max Therapeutics.

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

References

1. Spellberg B, Lipsky BA. Systemic antibiotic therapy for chronic osteomyelitis in adults. Clin Infect Dis. 2012;54(3):393–407.
2. Kremers HM, Nwojo ME, Ransom JE, Wood-Wentz CM, Melton LJ 3rd, Huddleston PM 3rd. Trends in the epidemiology of osteomyelitis: a population-based study, 1969 to 2009. J Bone Jt Surg Am. 2015;97(10):837–45.
3. Lew DP, Waldvogel FA. Osteomyelitis. N Engl J Med. 1997;336(14):999–1007.
4. Berbari E, Steckelberg J, Osmond D. Osteomyelitis. In: Mandell G, Bennett J, Dolin R, editors. Principles and practice of infectious diseases. 7th ed. Philadelphia: Elsevier Inc.; 2010. p. 1457–1468.
5. Schmitt SK. Osteomyelitis. Infect Dis Clin N Am. 2017;31(2):325–38.
6. Lew DP, Waldvogel FA. Osteomyelitis. Lancet. 2004;364(9431):369–79.
7. Cierny G 3rd, Mader JT, Pennick JJ. A clinical staging system for adult osteomyelitis. Clin Orthop Relat Res. 2003;414:7–24.
8. Hatzenbuehler J, Pulling TJ. Diagnosis and management of osteomyelitis. Am Fam Physician. 2011;84(9):1027–33.
9. Momodu I, Saveliya V. Osteomyelitis. Treasure Island: StatPearls Publishing; 2019.
10. Mader JT, Shirtliff M, Calhoun JH. Staging and staging the surgeon’s and microbiologist’s perspectives. Injury. 2011;42(Suppl 5):S18–23.
11. Haidar R, Der Boghossian A, Atiyeh B. Duration of post-surgical antibiotics in chronic osteomyelitis: empiric or evidence-based? Int J Infect Dis. 2010;14(9):e752–e758758.
12. Waldvogel FA, Medoff G, Swartz MN. Osteomyelitis: a review of clinical features, therapeutic considerations and unusual aspects. N Engl J Med. 1970;282(4):198–206.
13. Waldvogel FA, Medoff G, Swartz MN. Osteomyelitis: a review of clinical features, therapeutic considerations and unusual aspects (second of three parts). N Engl J Med. 1970;282(5):260–6.
14. Waldvogel FA, Medoff G, Swartz MN. Osteomyelitis: a review of clinical features, therapeutic considerations and unusual aspects. 3. Osteomyelitis associated with vascular insufficiency. N Engl J Med. 1970;282(6):316–22.
15. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis. 2011;52(3):285–92.
16. Boucher H, Miller LG, Razonable RR. Serious infections caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2010;51(Suppl 2):S183–S197197.
17. Li HK, Rombach I, Zambellas R, Walker AS, McNally MA, Atkins BL, et al. Oral versus intravenous antibiotics for bone and joint infection. N Engl J Med. 2019;380(5):425–36.
18. Rybak MJ, Lomaestro BM, Rotschafer JC, McQuillan JR, Craig WA, Belleter M, et al. Therapeutic monitoring of vancomycin in adults summary of consensus recommendations from the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Pharmacotherapy. 2009;29(11):1275–9.
19. Jeffres MN. The whole price of vancomycin: toxicities, troughs, and time. Drugs. 2017;77(11):1143–54.
20. Turner RB, Wilson DE, Saedi-Kwong H, Chang E, Won R, Chan D, et al. Comparative analysis of neutropenia in patients receiving prolonged treatment with ceftaroline. J Antimicrob Chemother. 2018;73(3):772–8.
22. Moenster RP, Linneman TW, Call WB, Kay CL, McEvoy TA, Sanders JL. The potential role of newer gram-positive antibiotics in the setting of osteomyelitis of adults. J Clin Pharm Ther. 2013;38(2):89–96.

23. Watkins RR, Lemonovich TL, File TM Jr. An evidence-based review of linezolid for the treatment of methicillin-resistant Staphylococcus aureus (MRSA): place in therapy. Core Evid. 2012;7:131–43.

24. Nair MA, Yu VL. Linezolid-associated peripheral and optic neuropathy, lactic acidosis, and serotonin syndrome. Pharmacotherapy. 2007;27(8):1189–97.

25. Bodnar T, Starr K, Halter JB. Linezolid-associated hypoglycemia in a 64-year-old man with type 2 diabetes. Am J Geriatr Pharmacother. 2011;9(1):88–92.

26. Go AC, Golightly LK, Barber GR, Barron MA. Linezolid interaction with serotonin reuptake inhibitors: report of two cases and incidence assessment. Drug Metabol Drug Interact. 2010;25(1–4):41–7.

27. Mogle BT, Steele JM, Thomas SJ, Bohan KH, Kufel WD. Clinical review of delafloxacin: a novel anionic fluoroquinolone. J Antimicrob Chemother. 2018;73(6):1439–51.

28. Corey GR, Kabler H, Mehta P, Gupta S, Overcash JS, Porwal A, et al. Single-dose oritavancin in the treatment of acute bacterial skin infections. N Engl J Med. 2014;370(23):2180–90.

29. Corey GR, Good S, Jiang H, Moeck G, Wikler M, Green S, et al. Single-dose oritavancin versus 7–10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study. Clin Infect Dis. 2015;60(2):254–62.

30. Melinta Therapeutics I. Orbactiv® (oritavancin) Full Prescribing Information (Package insert). 2018.

31. Rubino CM, Bhavnani SM, Moeck G, Bellibas SE, Ambrose PG. Population pharmacokinetic analysis for a single 1,200-milligram dose of oritavancin using data from two pivotal phase 3 clinical trials. Antimicrob Agents Chemother. 2015;59(6):3365–72.

32. Rubino CM, Van Wart SA, Bhavnani SM, Ambrose PG, McCollem JS, Forrest A. Oritavancin population pharmacokinetics in healthy subjects and patients with complicated skin and skin structure infections or bacteremia. Antimicrob Agents Chemother. 2009;53(10):4422–8.

33. Lehoux D, Ostiguy V, Cadieux C, Malouin M, Belanger O, Far AR, et al. Oritavancin pharmacokinetics and bone penetration in rabbits. Antimicrob Agents Chemother. 2015;59(10):6501–5.

34. Mendes RE, Sader HS, Flamm RK, Farrell DJ, Jones RN. Oritavancin activity against Staphylococcus aureus causing invasive infections in U.S. and European hospitals: a 5-year international surveillance program. Antimicrob Agents Chemother. 2014;58(5):2921–4.

35. Duncan LR, Sader HS, Flamm RK, Jones RN, Mendes RE. Oritavancin in vitro activity against contemporary Staphylococcus aureus isolates responsible for invasive community- and healthcare-associated infections among patients in the United States (2013–2014). Diagn Microbiol Infect Dis. 2016;86(3):303–6.

36. Morrissey I, Seifert H, Canton R, Nordmann P, Stefani S, Macgowan A, et al. Activity of oritavancin against methicillin-resistant staphylococci, vancomycin-resistant enterococci and beta-haemolytic streptococci collected from western European countries in 2011. J Antimicrob Chemother. 2013;68(1):164–7.

37. Kelley A, Neesham-Grenon E, McKay G, Arhin FF, Harris R, Beveridge T, et al. Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro. Antimicrob Agents Chemother. 2009;53(3):918–25.

38. Mendes RE, Woosley LN, Farrell DJ, Sader HS, Jones RN. Oritavancin activity against vancomycin-susceptible and vancomycin-resistant Enterococci with molecularly characterized glycopeptide resistance genes recovered from bacteremic patients, 2009–2010. Antimicrob Agents Chemother. 2012;56(3):1639–42.

39. Delaportas DJ, Estrada SJ, Darmello M. Successful treatment of methicillin susceptible Staphylococcus aureus osteomyelitis with oritavancin. Pharmacotherapy. 2017;37(8):e90–e9292.

40. Schulz LT, Dworkin E, Dela-Pena J, Rose WE. Multiple-dose oritavancin evaluation in a retrospective cohort of patients with complicated infections. Pharmacotherapy. 2018;38(1):152–9.

41. Ruggero M, Ziegler M, Tebas P, Binkley A, Kelly B. Successful treatment of Methicillin-resistant Staphylococcus aureus vertebral osteomyelitis with outpatient oritavancin therapy. Infect Dis Clin Pract. 2018;26(3):141–4.

42. Stewart CL, Turner MS, Frens JJ, Snider CB, Smith JR. Real-world experience with oritavancin therapy in invasive gram-positive infections. Infect Dis Ther. 2017;6(2):277–89.

43. Daresh S, Wong B, Nizet V, Sakoulas G, Tran TT, Aitken SL. Treatment of multidrug-resistant vancomycin-resistant enterococcal faecium hardware-associated vertebral osteomyelitis with oritavancin plus ampicillin. Antimicrob Agents Chemother. 2019;63(7):e02622-18.

44. Chastain DB, Davis A. Treatment of chronic osteomyelitis with multidose oritavancin: a case series and literature review. Int J Antimicrob Agents. 2019;53(4):429–34.

45. Foster R, Philavong K, Weissman S, Tang X, Bookstaver B. Oritavancin for treatment of daptomycin nonsusceptible vancomycin-resistant enterococci osteomyelitis. Infect Dis Clin Pract. 2017;26(2):1.

46. Melinta Therapeutics I Clinical and Historic Registry and Orbactiv Medical Evaluation (CHROME) registry. 2018.

47. Roblot F, Besnier JM, Juhel L, Vidal C, Ragot S, Bastides F, et al. Optimal duration of antibiotic therapy in vertebral osteomyelitis. Semin Arthritis Rheum. 2007;36(5):269–77.

48. Kavanagh N, Ryan EJ, Sexton G, Fennell J, O’Rourke N, Whitehouse A, et al. Staphylococcal osteomyelitis: disease progression, treatment challenges, and future directions. Clin Microbiol Rev. 2018;31(2):e00844-17.

49. Dhahnd A, Sakoulas G. Reduced vancomycin susceptibility among clinical Staphylococcus aureus isolates (‘the MIR CReep’): implications for therapy. F1000 Med Rep. 2012;4:4.

50. Díaz R, Afreixo V, Ramalheira E, Rodrigues C, Gago B. Evaluation of vancomycin MIC creep in methicillin-resistant Staphylococcus aureus infections-a systematic review and meta-analysis. Clin Microbiol Infect. 2018;24(2):97–104.

51. Anastasio PJ, Woltzoff P, Galli A, Fan W. Single-Dose oritavancin compared to standard of care iv antibiotics for acute bacterial skin and skin structure infection in the outpatient setting: a retrospective real-world study. Infect Dis Ther. 2017;6(1):115–28.